Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.010
Sell
RSI(14)
27.116
Sell
STOCH(KDJ)(9,3,3)
12.446
Oversold
ATR(14)
0.040
High Vlolatility
CCI(14)
-97.865
Neutral
Williams %R
93.738
Oversold
TRIX(12,20)
-1.174
Sell
StochRSI(14)
58.474
Sell
Icecure Medical Ltd
ICCM0.710USD
-0.014-1.95%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
41.67MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Icecure Medical Ltd
Currency: USD Updated: 2025-11-05Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is low. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Icecure Medical Ltd's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
2.917
Target Price
+302.80%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Icecure Medical Ltd Highlights
StrengthsRisks
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.29M.
Overvalued
The company’s latest PE is -2.53, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 241.02K shares, decreasing 18.19% quarter-over-quarter.
Held by Ken Fisher
Star Investor Ken Fisher holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.36.
Financial Health
Currency: USD Updated: 2025-11-05The company's current financial score is 5.59, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 525.00K, representing a year-over-year decrease of 48.07%, while its net profit experienced a year-over-year decrease of 9.19%.
Score
Financials
6.49
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.49
Operational Efficiency
2.57
Growth Potential
4.32
Shareholder Returns
7.11
Icecure Medical Ltd's Company Valuation
Currency: USD Updated: 2025-11-05The company’s current valuation score is 7.17, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -2.53, which is -44.20% below the recent high of -1.41 and -103.61% above the recent low of -5.15.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 130/210
No Data
Earnings Forecast
Currency: USD Updated: 2025-11-05The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Icecure Medical Ltd is 3.00, with a high of 3.25 and a low of 2.50.
Score
Support & Resistance
No Data
Analyst Rating
Based on
3
analysts
Buy
Current Rating
2.917
Target Price
+302.80%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
89
Total
4
Median
7
Average
Company name
Ratings
Analysts
Icecure Medical Ltd
ICCM
3
Boston Scientific Corp
BSX
37
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
35
Veeva Systems Inc
VEEV
34
Thermo Fisher Scientific Inc
TMO
28
1
2
3
...
18
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-11-05The company’s current price momentum score is 6.26, which is lower than the Healthcare Equipment & Supplies industry's average of 6.82. Sideways: Currently, the stock price is trading between the resistance level at 0.91 and the support level at 0.60, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.717
Sell
MA10
0.750
Sell
MA20
0.800
Sell
MA50
0.939
Sell
MA100
0.953
Sell
MA200
1.076
Sell
Institutional Confidence
Currency: USD Updated: 2025-11-05Score
Institutional Shareholding
No Data
Risk Assessment
Currency: USD Updated: 2025-11-05The company’s current risk assessment score is 2.19, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 2.26. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
2.26
VaR
+8.53%
240-Day Maximum Drawdown
+54.19%
240-Day Volatility
+97.15%
Return
Best Daily Return
60 days
+20.80%
120 days
+20.80%
5 years
+734.11%
Worst Daily Return
60 days
-9.65%
120 days
-9.65%
5 years
-46.92%
Sharpe Ratio
60 days
-0.30
120 days
-0.79
5 years
+0.56
Risk Assessment
Maximum Drawdown
240 days
+54.19%
3 years
+68.51%
5 years
--
Return-to-Drawdown Ratio
240 days
+0.30
3 years
-0.24
5 years
--
Skewness
240 days
+0.96
3 years
+3.92
5 years
+27.72
Volatility
Realised Volatility
240 days
+97.15%
5 years
--
Standardised True Range
240 days
+10.89%
5 years
--
Downside Risk-Adjusted Return
120 days
-146.97%
240 days
-146.97%
Maximum Daily Upside Volatility
60 days
+113.74%
Maximum Daily Downside Volatility
60 days
+66.54%
Liquidity
Average Turnover Rate
60 days
+2.66%
120 days
+1.56%
5 years
--
Turnover Deviation
20 days
+36.13%
60 days
+15.71%
120 days
-31.84%
Peer Comparison
Healthcare Equipment & Supplies
Icecure Medical Ltd
ICCM
5.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
CSTL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
COR
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
